3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
18
Unknown
1
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Genitourinary
1
Breast
1
Conditions
Prostatic Neoplasms
1
Neoplasm Metastasis
1
Motor Activity
1
Interventions
pembrolizumab
65
Nivolumab
58
Magnetic Resonance Spectroscopy
53
enzalutamide
39
Abiraterone Acetate
37
Radiosurgery
36
Gemcitabine
35
Specimen Handling
32
Radiotherapy
32
Ipilimumab
32
Androgen Antagonists
32
Prednisone
31
apalutamide
28
Cisplatin
28
Docetaxel
27
Leuprolide
26
atezolizumab
25
Carboplatin
25
durvalumab
23
cabozantinib
23
darolutamide
20
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
19
olaparib
18
Goserelin
17
Radiation
16
Gonadotropin-Releasing Hormone
16
Biopsy
16
gallium 68 PSMA-11
15
Pluvicto
15
avelumab
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Psychiatric Rehabilitation
×
Genitourinary
×
Clear all
NCT02730338
2024-11-27
INTERVAL
Movember Foundation
Phase NA
Active not recruiting
866 enrolled